Allogene Therapeutics ALLO Shares Reserved for Future Issuance Under Stock Plans
Shares Reserved for Future Issuance Under Stock Plans at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's shares reserved for future issuance under stock plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's shares reserved for future issuance under stock plans?
- Allogene Therapeutics (ALLO) reported shares reserved for future issuance under stock plans of 9M in Q1 2026.
- How has Allogene Therapeutics's shares reserved for future issuance under stock plans changed year-over-year?
- Allogene Therapeutics's shares reserved for future issuance under stock plans increased by 72.5% year-over-year, from 5.2M to 9M.
- What does shares reserved for future issuance under stock plans mean?
- This represents the total number of common shares authorized and set aside for future issuance to employees and directors under equity compensation plans. It provides insight into the potential future dilution of existing shareholders. Investors monitor this to assess the firm's long-term incentive structure.